Amgen Inc (AMGN)
Cash ratio
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | US$ in thousands | 11,973,000 | 9,011,000 | 9,301,000 | 9,708,000 | 10,944,000 | 34,741,000 | 34,248,000 | 31,560,000 | 7,629,000 | 9,502,000 | 5,203,000 | 6,528,000 | 7,989,000 | 11,969,000 | 6,630,000 | 6,112,000 | 6,266,000 | 9,087,000 | 9,145,000 | 7,687,000 |
| Short-term investments | US$ in thousands | — | — | — | — | 10,944,000 | 0 | 0 | 1,000 | 1,676,000 | 1,976,000 | 1,980,000 | 16,000 | 48,000 | 952,000 | 1,452,000 | 4,454,000 | 4,381,000 | 3,273,000 | 2,276,000 | 325,000 |
| Total current liabilities | US$ in thousands | 23,099,000 | 20,312,000 | 21,517,000 | 19,714,000 | 18,392,000 | 16,954,000 | 17,097,000 | 14,215,000 | 15,687,000 | 14,331,000 | 12,618,000 | 12,886,000 | 12,184,000 | 14,842,000 | 14,585,000 | 12,869,000 | 11,653,000 | 9,953,000 | 10,523,000 | 11,827,000 |
| Cash ratio | 0.52 | 0.44 | 0.43 | 0.49 | 1.19 | 2.05 | 2.00 | 2.22 | 0.59 | 0.80 | 0.57 | 0.51 | 0.66 | 0.87 | 0.55 | 0.82 | 0.91 | 1.24 | 1.09 | 0.68 |
December 31, 2024 calculation
Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($11,973,000K
+ $—K)
÷ $23,099,000K
= 0.52
The cash ratio for Amgen Inc has fluctuated over the periods provided.
From March 31, 2020, to December 31, 2021, the cash ratio stayed mostly below 1, indicating that the company had minimal cash reserves relative to its current liabilities during this period. Notably, the ratio saw a peak of 1.24 on September 30, 2020, but generally stayed below the ideal threshold of 1.
However, starting from March 31, 2022, the cash ratio experienced a significant improvement, surpassing 1 and reaching 2.22 on March 31, 2023. This indicates that Amgen Inc had a substantial increase in its cash reserves in relation to its current liabilities during this period.
Subsequently, the cash ratio decreased slightly in the following periods but remained above 1, reflecting a healthier liquidity position for the company compared to the earlier years.
Overall, the trend in the cash ratio suggests that Amgen Inc improved its liquidity position significantly from 2022 onwards, indicating a better ability to cover its short-term obligations with its available cash resources.
Peer comparison
Dec 31, 2024